Midland Wealth Advisors LLC Sells 644 Shares of Eli Lilly and Company $LLY

Midland Wealth Advisors LLC lowered its holdings in Eli Lilly and Company (NYSE:LLY) by 22.6% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,208 shares of the company’s stock after selling 644 shares during the quarter. Midland Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $1,685,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Hemenway Trust Co LLC raised its stake in Eli Lilly and Company by 48.1% during the 3rd quarter. Hemenway Trust Co LLC now owns 17,707 shares of the company’s stock valued at $13,511,000 after purchasing an additional 5,752 shares during the last quarter. Burling Wealth Partners LLC lifted its stake in shares of Eli Lilly and Company by 20.4% in the third quarter. Burling Wealth Partners LLC now owns 12,523 shares of the company’s stock valued at $9,555,000 after buying an additional 2,120 shares during the period. King Luther Capital Management Corp increased its stake in Eli Lilly and Company by 11.5% during the third quarter. King Luther Capital Management Corp now owns 185,655 shares of the company’s stock valued at $141,655,000 after acquiring an additional 19,172 shares during the period. CFO4Life Group LLC raised its holdings in Eli Lilly and Company by 0.7% in the 3rd quarter. CFO4Life Group LLC now owns 1,841 shares of the company’s stock valued at $1,405,000 after acquiring an additional 13 shares in the last quarter. Finally, Harold Davidson & Associates Inc. lifted its position in shares of Eli Lilly and Company by 44.5% in the 3rd quarter. Harold Davidson & Associates Inc. now owns 4,599 shares of the company’s stock worth $3,509,000 after acquiring an additional 1,417 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Long‑term VIVID‑2 data show Omvoh (mirikizumab) delivered durable, steroid‑free remission through three years in Crohn’s disease with very low surgery and hospitalization rates, bolstering Omvoh’s positioning in IBD and its multi‑year commercial potential. Patients with Crohn’s disease maintained steroid-free remission for three years with Lilly’s Omvoh (mirikizumab-mrkz)
• Positive Sentiment: Phase 3b data show Lilly’s Zepbound (tirzepatide) combined with Taltz (ixekizumab) delivered superior efficacy in a first‑of‑its‑kind trial, supporting cross‑franchise use (psoriasis + obesity) and potential expansion of indications. Lilly chalks up another trial win for Zepbound-Taltz combo in bid to break down psoriasis, obesity ‘silos’
• Positive Sentiment: CSL signed a licensing deal with Lilly for clazakizumab worth up to $100M upfront/near‑term consideration, providing near‑term non‑dilutive revenue and validation of Lilly’s immunology assets. Eli Lilly Enters $100 Million Licensing Agreement with CSL Limited for Clazakizumab
• Positive Sentiment: Daiwa raised its price target on LLY to $1,250 and kept a buy rating, reinforcing analyst optimism and providing support for further upside from current levels. Daiwa Securities adjusts price target on Eli Lilly to $1,250
• Positive Sentiment: Reports that Medicare expansion/easing around GLP‑1 coverage is reducing pricing uncertainty for weight‑loss drugs, which could support higher volume and monetization for Lilly’s GLP‑1 portfolio. Eli Lilly and Company (LLY) Gains as Medicare Expansion of GLP-1 Weight Loss Drugs Eases Pricing Concerns
• Neutral Sentiment: Lilly launched a Phase 2 trial for brenipatide in opioid use disorder (RENEW‑Op‑1), expanding the pipeline into addiction medicine — a longer‑term, higher‑uncertainty opportunity. Eli Lilly Pushes Into Opioid Use Disorder With New Brenipatide Phase 2 Trial
• Neutral Sentiment: Analyses note Lilly’s next‑gen obesity pipeline (oral orforglipron, retatrutide) must fend off intensifying competition — a reminder growth may require ongoing R&D and price/mix management. Can LLY’s Next‑Gen Obesity Pipeline Sustain Growth Amid Competition?
• Neutral Sentiment: Media mentions (e.g., Jim Cramer) and a Team USA ambassador tie‑in raise visibility but have limited direct financial impact. Jim Cramer Discusses Eli Lilly (LLY) & Weight Loss Drugs
• Negative Sentiment: An analyst piece warns Lilly’s GLP‑1 leadership faces hidden risks — competition, pricing pressure and eventual market maturation — highlighting why current lofty multiples could be vulnerable if growth normalizes. Warning: This Skyrocketing Stock Has a Hidden Risk

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Berenberg Bank upped their target price on Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a research note on Tuesday, December 2nd. CICC Research increased their price objective on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a research note on Wednesday, February 11th. Scotiabank reaffirmed an “outperform” rating and set a $1,300.00 price objective on shares of Eli Lilly and Company in a report on Thursday, February 5th. JPMorgan Chase & Co. upped their target price on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Finally, Leerink Partners raised their price target on shares of Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the stock an “outperform” rating in a research note on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,224.69.

Eli Lilly and Company Trading Up 0.2%

Shares of LLY stock opened at $1,023.10 on Friday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The company has a market capitalization of $965.15 billion, a P/E ratio of 44.58, a P/E/G ratio of 1.19 and a beta of 0.39. The firm has a 50-day moving average price of $1,055.22 and a 200 day moving average price of $913.92. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. During the same period in the prior year, the firm earned $5.32 earnings per share. The company’s quarterly revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is 30.15%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.